A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
A phase 1/2 trial of CM336_group 1 in multiple myeloma, run by Keymed Biosciences Co.Ltd, now recruiting.
Overview
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05299424 by Keymed Biosciences Co.Ltd, with 48 participants planned, started 2022-08-09 and due to reach its primary completion in 2026-12. Interventions recorded: CM336_group 1, CM336_group 2a, CM336_group 2b, CM336_group 3a, CM336_group 3b and CM336_group 4a.
Similar pages
not linked directly; found by shared links- TrialA Study of CM350 in Patients With Advanced Solid Tumors
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
- TrialStudy of CM518D1 in Patients With Advanced Solid Tumors
Shares Keymed Biosciences (KYM Biosciences) and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialSARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.